These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 30902916)

  • 1. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
    Sise ME; Seethapathy H; Reynolds KL
    Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
    Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
    BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
    Franzin R; Netti GS; Spadaccino F; Porta C; Gesualdo L; Stallone G; Castellano G; Ranieri E
    Front Immunol; 2020; 11():574271. PubMed ID: 33162990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
    Chang CY; Park H; Malone DC; Wang CY; Wilson DL; Yeh YM; Van Boemmel-Wegmann S; Lo-Ciganic WH
    JAMA Netw Open; 2020 Mar; 3(3):e201611. PubMed ID: 32211869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute kidney injury from immune checkpoint inhibitor use.
    Gordon L; Dokouhaki P; Hagel K; Prasad B
    BMJ Case Rep; 2019 Oct; 12(10):. PubMed ID: 31653633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal adverse effects of immune checkpoints inhibitors in clinical practice: ImmuNoTox study.
    Espi M; Teuma C; Novel-Catin E; Maillet D; Souquet PJ; Dalle S; Koppe L; Fouque D
    Eur J Cancer; 2021 Apr; 147():29-39. PubMed ID: 33607383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.
    Abdelrahim M; Mamlouk O; Lin H; Lin J; Page V; Abdel-Wahab N; Swan J; Selamet U; Yee C; Diab A; Suki W; Abudayyeh A
    Oncoimmunology; 2021 May; 10(1):1927313. PubMed ID: 34104543
    [No Abstract]   [Full Text] [Related]  

  • 9. Utilization and toxicity patterns of 2-weekly (Q2W) versus 4-weekly (Q4W) nivolumab for treatment of adjuvant and metastatic melanoma at BC cancer.
    Truong J; Yeung SST; Kletas V; de Lemos M; Schaff K; Nakashima L
    J Oncol Pharm Pract; 2024 Sep; 30(6):1016-1022. PubMed ID: 37654194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
    BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nephrotoxicity in the Age of Immune Checkpoint Inhibitors: Mechanisms, Diagnosis, and Management.
    Moturi K; Sharma H; Hashemi-Sadraei N
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immune checkpoint inhibitor therapy with nivolumab and ipilimumab causing acute-onset type 1 diabetes mellitus following a single administration: two case reports.
    Zezza M; Kosinski C; Mekoguem C; Marino L; Chtioui H; Pitteloud N; Lamine F
    BMC Endocr Disord; 2019 Dec; 19(1):144. PubMed ID: 31870373
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    Wu CE; Yang CK; Peng MT; Huang PW; Chang CF; Yeh KY; Chen CB; Wang CL; Hsu CW; Chen IW; Lin CT; Ueng SH; Lin G; Lin YF; Cheng CY; Chang JW
    BMC Cancer; 2020 Oct; 20(1):1018. PubMed ID: 33087090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitors associated granulomatous small vessel vasculitis accompanied with tubulointerstitial nephritis: a case report.
    Tominaga K; Takeuchi K; Takakuma S; Sakamoto E; Hatanaka S; Kajimoto Y; Toda E; Terasaki Y; Kunugi S; Terasaki M; Shimizu A
    BMC Nephrol; 2023 Mar; 24(1):48. PubMed ID: 36894873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors.
    Gallan AJ; Alexander E; Reid P; Kutuby F; Chang A; Henriksen KJ
    Am J Kidney Dis; 2019 Dec; 74(6):853-856. PubMed ID: 31204194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variable Expression of Programmed Cell Death Protein 1-Ligand 1 in Kidneys Independent of Immune Checkpoint Inhibition.
    Hakroush S; Kopp SB; Tampe D; Gersmann AK; Korsten P; Zeisberg M; Tampe B
    Front Immunol; 2020; 11():624547. PubMed ID: 33552089
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of emergency department visits and immune-related adverse effects (irAEs) in patients treated with nivolumab.
    Kudu E; Akdag G; Yildirim ME
    Support Care Cancer; 2024 Sep; 32(10):646. PubMed ID: 39251491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitor (nivolumab)-associated kidney injury and the importance of recognizing concomitant medications known to cause acute tubulointerstitial nephritis: a case report.
    Koda R; Watanabe H; Tsuchida M; Iino N; Suzuki K; Hasegawa G; Imai N; Narita I
    BMC Nephrol; 2018 Feb; 19(1):48. PubMed ID: 29486725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
    Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
    J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pembrolizumab Induced Acute Kidney Injury and Liver Injury in a Patient with Malignant Melanoma.
    DeVries JD; Huber M; Sulaiman R; Singal AK
    S D Med; 2022 Apr; 75(4):162-165. PubMed ID: 35709347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.